Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
4507 | Tokyo | JPY | Delayed | |
SGIOY | OTC Markets | USD | Delayed | |
4507 | Frankfurt | EUR | Delayed |
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Name | Age | Since | Title |
---|---|---|---|
Hiroshi Ozaki | 71 | 2019 | Independent Outside Director |
Akira Okamoto | 68 | 2015 | Standing Corporate Auditor |
Isao Teshirogi | 64 | 2002 | CEO, President & Representative Director |
Fumi Takatsuki | 48 | 2020 | Independent Outside Director |
Takuko Yamada-Sawada | 68 | 2011 | Vice Chairman of the Board |
Tsuguoki Fujinuma | 79 | 2019 | Independent Outside Corporate Auditor |
Ikuo Kato | 69 | 2013 | Standing Corporate Auditor |
Shuichi Okuhara | 55 | 2020 | Outside Corporate Auditor |
Yoriko Goto | - | 2023 | Outside Corporate Auditor |
Keiichi Ando | 72 | 2016 | Independent Chairperson of the Board |
Takaoki Fujiwara | 71 | 2018 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review